Evidence standard: Claims are graded by study type. Speculative claims are labeled. No affiliate rankings. No fabricated statistics.
Key Takeaways
- The TIPO-1 phase II RCT (n=203) showed 10.6% body weight loss at 24 weeks with 1.0 mg oral daily versus 2.2% with placebo, making tesofensine one of the strongest weight-loss signal compounds in phase II history.
- No approved injectable form exists. Compounded tesofensine injection is a research-use preparation; starting subcutaneous dose in clinical practice is typically 0.25 mg daily, not the 1.0 mg that produced the strongest trial results.
- Tesofensine is a triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin), meaning its cardiovascular risk profile resembles stimulants, not GLP-1 drugs. Heart rate elevation is documented in trial data.
- Bacteriostatic water is required for reconstitution, not sterile water, because multi-dose vials need a preservative. Sterile water lacks benzyl alcohol and allows microbial growth within days after opening.
- A legitimate compounded vial COA must include HPLC purity, mass spectrometry identity, endotoxin level, and sterility result. If any of those four are absent, the product should not be injected.
What is tesofensine injection and does it work?
Tesofensine injection is a compounded subcutaneous preparation of tesofensine, a triple monoamine reuptake inhibitor originally developed by NeuroSearch for Parkinson's and Alzheimer's disease that was redirected to obesity after unexpected weight-loss signals in neurological trials. The best human evidence (TIPO-1, a 24-week phase II RCT) showed 10.6% body weight loss at the 1.0 mg oral daily dose. The injectable route lacks its own phase III data, so efficacy claims for the injection specifically rest on pharmacokinetic bridging, not direct injection trial outcomes.
Table of Contents
- Evidence Ledger: What the Data Actually Supports
- Mechanism With Numbers: How Tesofensine Reduces Body Weight
- Injection Protocol: Reconstitution, Dose, and Site
- What Most Pages Get Wrong About Tesofensine Injection
- The Chemistry Behind Storage and Stability Rules
- Honest Head-to-Head: Tesofensine vs. Alternatives
- Label and COA Literacy: How to Judge Your Vial
- Side Effects, Contraindications, and Risk Stratification
- FAQ
- Sources
- Disclaimers
Evidence Ledger: What the Data Actually Supports
| Claim | Best Evidence Type | Key Study / Source | Effect Direction | Confidence |
|---|---|---|---|---|
| Weight loss at 0.5 mg oral daily (~6.7% body weight at 24 weeks) | Phase II RCT, n=203 | Astrup et al. 2008, Lancet | Positive | Moderate |
| Weight loss at 1.0 mg oral daily (~10.6% body weight at 24 weeks) | Phase II RCT, n=203 | Astrup et al. 2008, Lancet | Positive, strong signal | Moderate |
| Subcutaneous injectable bioavailability equivalent to oral | Pharmacokinetic inference, no dedicated human PK trial for injection published | Mechanism-based extrapolation | Plausible but unconfirmed | Low |
| Heart rate increase (~6 to 8 bpm at 0.5 mg) | Phase II RCT safety data | Astrup et al. 2008, Lancet | Adverse, dose-dependent | High |
| Appetite suppression via hypothalamic dopamine and norepinephrine pathways | Animal studies, mechanistic | Rodent data, Sjodin et al. 2010 | Positive in animals | Low for humans |
| Long-term cardiovascular safety | Not studied | No phase III cardiovascular outcomes trial completed | Unknown | Very Low |
| Superiority to GLP-1 agents head-to-head | No head-to-head RCT | Indirect comparison only | Not established | Very Low |
Mechanism With Numbers: How Tesofensine Reduces Body Weight
Tesofensine (NS2330) inhibits the presynaptic reuptake transporters for dopamine (DAT), norepinephrine (NET), and serotonin (SERT). This triple blockade increases monoamine availability in the synaptic cleft, particularly in the hypothalamus and mesolimbic reward circuitry, which suppresses appetite and may increase basal metabolic rate via sympathetic activation.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →The molecular weight of tesofensine free base is approximately 373.94 g/mol. Its oral bioavailability was reported as high in phase I work by NeuroSearch, which is part of why the injectable route was explored later as a delivery variant, not as the original development pathway.
The Astrup et al. 2008 Lancet trial (n=203, 24 weeks) reported placebo-subtracted weight loss of roughly 4.5% at 0.5 mg and approximately 8.4% at 1.0 mg daily. These are among the largest phase II weight-loss signals recorded before the GLP-1 era. However, the mechanism also predicts stimulant-class side effects, the same dopaminergic and noradrenergic activity that reduces appetite also raises heart rate and blood pressure. This mechanism does NOT prove cardiovascular safety at long-term use, because no long-term outcomes trial has been completed.
Injection Protocol: Reconstitution, Dose, and Site
Reconstitution Math
If your compounded vial contains 5 mg of lyophilized tesofensine and you want a working concentration of 1 mg per mL, add exactly 5 mL of bacteriostatic water. If you want 2 mg per mL to reduce injection volume, add 2.5 mL of bacteriostatic water. Always add the diluent along the vial wall slowly. Swirl gently for 30 to 60 seconds. Never shake, because vigorous agitation can denature peptide structure through mechanical shear stress.
| Vial Size | BacWater Added | Resulting Concentration | Volume for 0.25 mg Dose | Volume for 0.5 mg Dose |
|---|---|---|---|---|
| 5 mg | 5 mL | 1 mg/mL | 0.25 mL (25 units on U-100 syringe) | 0.5 mL (50 units) |
| 5 mg | 2.5 mL | 2 mg/mL | 0.125 mL (12.5 units) | 0.25 mL (25 units) |
| 10 mg | 10 mL | 1 mg/mL | 0.25 mL (25 units) | 0.5 mL (50 units) |
Injection Technique
- Use a 29 to 31 gauge, 4 to 8 mm insulin-type needle.
- Clean the injection site with an alcohol swab and let it fully dry before inserting the needle. Wet alcohol entering the subcutaneous space stings and can degrade the compound at the injection point.
- Pinch the skin, insert at a 45 to 90 degree angle depending on body fat thickness, inject slowly, and withdraw. Do not rub afterward.
- Rotate among abdomen, outer thigh, and lateral upper arm with each injection. Repeat injections at the same site cause localized lipodystrophy over time.
- Inject once daily at the same time each day to maintain stable plasma levels given the compound's reported multi-day half-life in oral pharmacokinetic data.
Titration Schedule (Prescriber-Directed, General Reference Only)
| Weeks | Typical Starting Dose | Rationale |
|---|---|---|
| 1 to 4 | 0.25 mg daily | Establish tolerability, monitor heart rate and blood pressure |
| 5 to 8 | 0.5 mg daily (if well tolerated) | Dose where meaningful weight-loss signal appeared in TIPO-1 |
| 9 onward | Up to 1.0 mg daily (prescriber decision) | Strongest trial signal dose; highest side-effect burden |
What Most Pages Get Wrong About Tesofensine Injection
The most common error on competitor pages is presenting the TIPO-1 weight-loss percentages as if they apply directly to injectable tesofensine. They do not. The TIPO-1 trial used oral administration. An injectable form changes the absorption kinetics, bypasses first-pass metabolism entirely, and may produce different peak plasma concentrations for the same nominal dose. That means the effective dose for injection is not simply a 1:1 translation from the oral trial doses, and any compounding pharmacy or protocol claiming exact equivalence without injectable-specific pharmacokinetic data is extrapolating beyond the evidence.
A second omission is the cardiovascular signal. Virtually every medspa content page emphasizes the weight-loss percentages and minimizes that the 1.0 mg arm in TIPO-1 produced the highest rate of adverse cardiovascular events among the active groups, which is why the drug's development was cautious and it remains without phase III completion or regulatory approval. This is not a minor footnote.
A third error is treating compounded tesofensine injection as a peptide in the conventional sense. Tesofensine is a small molecule, not a peptide. Its stability, storage behavior, and bioavailability profile differ from peptide hormones like semaglutide or BPC-157. Calling it a peptide is a category error that matters when thinking about formulation and degradation.
The Chemistry Behind Storage and Stability Rules
Tesofensine is a piperidine-based small molecule. Unlike peptides, it does not contain amide bonds susceptible to hydrolysis in the same way. However, once reconstituted in aqueous solution, it is subject to oxidative degradation, pH-dependent instability, and microbial contamination.
Bacteriostatic water contains 0.9% benzyl alcohol as a preservative. Benzyl alcohol inhibits microbial growth by disrupting cell membranes. This is critical for multi-dose vials because each draw introduces a small contamination risk. Sterile water for injection contains no preservative and would allow microbial proliferation within days of the first puncture. Using sterile water in a multi-dose vial is a clinically meaningful error, not a minor formulation preference.
Refrigeration at 2 to 8 degrees Celsius slows oxidative degradation and reduces hydrolysis rates in aqueous solution. Freezing a reconstituted vial risks precipitation or structural change depending on the excipients used. Keep reconstituted vials refrigerated, not frozen, and protected from direct light, because UV radiation can drive photodegradation of aromatic ring-containing small molecules, which tesofensine contains in its structure.
A visibly cloudy or particulate solution after reconstitution indicates either aggregation, contamination, or degradation. Discard it. The financial loss from discarding a compromised vial is trivially small compared to the risk of injecting a contaminated preparation subcutaneously.
Honest Head-to-Head: Tesofensine vs. Alternatives
| Factor | Tesofensine (injection) | Semaglutide (Ozempic/Wegovy) | Phentermine (oral) | Tirzepatide (Mounjaro/Zepbound) |
|---|---|---|---|---|
| Regulatory Status | Not approved, compounded research use | FDA approved for obesity (Wegovy) | FDA approved, schedule IV | FDA approved for obesity (Zepbound) |
| Mechanism | Triple monoamine reuptake inhibition | GLP-1 receptor agonist | Norepinephrine releaser | GLP-1 and GIP dual agonist |
| Best Phase Evidence | Phase II only (n=203, 24 weeks) | Phase III, large outcomes trials (STEP program) | Multiple RCTs, decades of post-market data | Phase III, SURMOUNT program |
| Weight Loss Signal (best arm, approx.) | ~10.6% at 24 weeks (oral 1.0 mg) | ~15% at 68 weeks (2.4 mg weekly) | ~5 to 7% over 3 to 6 months | ~20 to 22% at 72 weeks |
| Cardiovascular Risk | Elevated heart rate documented; no CVOT completed | Cardiovascular benefit shown in SELECT trial | Elevated heart rate and BP; use with caution in CVD | Cardiovascular benefit under study (SURPASS-CVOT) |
| Where Tesofensine Loses | Evidence depth, regulatory oversight, long-term safety data, supply chain certainty | N/A (reference) | Weaker weight loss, addiction risk | N/A (reference) |
| Potential Niche Advantage | Distinct mechanism may suit GLP-1 non-responders (speculative; no trial data) | Proven safety, insurance coverage | Low cost, fast onset | Strongest phase III weight signal to date |
Label and COA Literacy: How to Judge Your Vial
Before injecting any compounded tesofensine, request the certificate of analysis from the compounding pharmacy. A minimum acceptable COA contains all four of the following:
- HPLC purity: Should show at least 98% purity of tesofensine. Peaks at unexpected retention times indicate impurities or degradants.
- Mass spectrometry identity confirmation: The measured molecular weight should match the expected value for tesofensine (the monohydrate salt form used in many formulations has a different mass than the free base; confirm which the COA references).
- Endotoxin testing: Expressed in EU/mL or EU/mg. Limits for injectable preparations follow USP standards. High endotoxin causes fever, inflammation, and septic-like responses. This is not optional testing.
- Sterility testing: Confirmation that no microbial growth was detected under USP sterility conditions.
Red flags on a label include: no lot number, no compounding pharmacy name and license number, no beyond-use date, or a COA that only shows purity without identity or endotoxin data. Any of these alone is a reason to pause.
Side Effects, Contraindications, and Risk Stratification
The TIPO-1 trial documented these side effects at rates higher than placebo in the active groups: dry mouth, nausea, constipation, insomnia, and heart rate elevation. At 0.5 mg, heart rate increases of roughly 6 to 8 beats per minute were recorded. At 1.0 mg, the cardiovascular signal was more pronounced, contributing to the risk-benefit caution that slowed phase III progression.
Absolute contraindications based on mechanism:
- Concurrent use of monoamine oxidase inhibitors (MAOI), including selegiline. Combining any monoamine reuptake inhibitor with an MAOI creates serious risk of hypertensive crisis and serotonin syndrome.
- Uncontrolled hypertension or resting tachycardia above 100 bpm.
- Personal or family history of serious structural cardiac disease.
- Active eating disorder diagnosis.
- Concurrent use of other serotonergic agents (SSRIs, SNRIs, triptans) without explicit prescriber management of serotonin syndrome risk.
Monitoring during use: Check resting heart rate and blood pressure before starting, at 4 weeks, and at every dose increase. Any sustained heart rate increase above 10 bpm from baseline warrants dose reduction or discontinuation discussion with your prescriber.
FAQ
What is the standard tesofensine injection dose?
The TIPO-1 phase II trial used 0.25 mg, 0.5 mg, and 1.0 mg oral daily doses. Compounded injectable formulations are typically prescribed starting at 0.25 mg subcutaneously once daily, titrated upward based on tolerability. No injectable-specific phase III data exist yet.
How do you reconstitute tesofensine for injection?
Add bacteriostatic water (not sterile water) slowly along the vial wall. Gently swirl, never shake. Standard reconstitution targets a concentration of 1 mg per mL. Confirm the final volume by reading the label concentration, then calculate your draw volume from there.
Where do you inject tesofensine?
Subcutaneous injection into the abdomen (at least 2 inches from the navel), outer thigh, or lateral upper arm. Rotate sites with each injection to reduce local irritation. Do not inject into muscle unless a prescriber specifically directs otherwise.
How long does tesofensine take to work for weight loss?
In the TIPO-1 trial, significant weight separation from placebo was observable by weeks 4 to 8, with maximum effect measured at week 24. Expect several weeks before meaningful scale movement.
What are the main side effects of tesofensine injection?
The most common side effects from trial data are dry mouth, nausea, constipation, insomnia, and elevated heart rate. Heart rate increases of roughly 6 to 8 beats per minute were recorded in the TIPO-1 trial at the 0.5 mg dose, which is clinically relevant for anyone with cardiovascular risk.
How should tesofensine injection be stored?
Unreconstituted lyophilized powder should be refrigerated at 2 to 8 degrees Celsius and protected from light. After reconstitution with bacteriostatic water, store at 2 to 8 degrees Celsius and use within 28 days. Discard if the solution appears cloudy or particulate.
Is tesofensine FDA approved?
No. Tesofensine is not FDA approved for any indication. It remains a research compound. Compounded injectable preparations exist outside FDA-approved drug pathways and carry different regulatory and quality assurance considerations than approved drugs.
Can you combine tesofensine with semaglutide or other GLP-1 agents?
No combination human trial data exist. Mechanistically, both increase weight loss by different pathways, but stacking raises the risk of additive cardiovascular effects, excessive appetite suppression, and nutrient deficiency. Combination use requires close prescriber supervision and is not standard practice.
What does a legitimate tesofensine vial COA show?
A legitimate certificate of analysis should include HPLC purity (at least 98%), identity confirmation by mass spectrometry, endotoxin testing results, sterility testing, and the compound's molecular weight confirmation. Reject any COA that lacks endotoxin and sterility data.
How is tesofensine different from phentermine or semaglutide?
Tesofensine is a triple monoamine reuptake inhibitor blocking dopamine, norepinephrine, and serotonin transporters. Phentermine is primarily a norepinephrine releaser. Semaglutide is a GLP-1 receptor agonist working on gut-brain signaling. Each has a distinct mechanism, evidence base, and risk profile.
What needle gauge is used for subcutaneous tesofensine injection?
A 29 to 31 gauge, 4 to 8 mm needle is standard for subcutaneous peptide injection. Use insulin-style syringes for volumes under 0.5 mL to improve accuracy. Always use a fresh needle for each injection.
What are the absolute contraindications for tesofensine?
Based on its mechanism as a monoamine reuptake inhibitor, contraindications include concurrent use of MAO inhibitors, uncontrolled hypertension, a history of serious cardiovascular disease, active eating disorders, and concurrent use of other serotonergic drugs due to serotonin syndrome risk.
Sources
- Astrup A, Madsbad S, Breum L, Jensen TJ, Kroustrup JP, Larsen TM. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9653):1906-1913. PMID: 19012960.
- Sjodin A, Gasteyger C, Nielsen AL, Raben A, Mikkelsen JD, Jensen J, Astrup A. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men. Int J Obes (Lond). 2010;34(11):1634-1643. PMID: 20531355.
- Appel L, Lossius AH, Bergstrom M, et al. Preferential dopamine release by tesofensine in prefrontal cortex. PLoS One. 2013;8(5):e63512. PMC: PMC3646807.
- United States Pharmacopeia. USP chapter 797: pharmaceutical compounding, sterile preparations. USP-NF. Current edition. Available at: www.usp.org
- Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. (SELECT trial, reference for GLP-1 cardiovascular evidence comparison).
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. (SURMOUNT-1, reference for tirzepatide weight-loss comparison).
Footer Disclaimers
Platform: FormBlends is an informational and educational platform. Nothing on this page constitutes medical advice, diagnosis, or a treatment recommendation. Always consult a licensed healthcare provider before initiating, modifying, or discontinuing any treatment protocol.
Research Compound: Tesofensine is not approved by the U.S. Food and Drug Administration (FDA) for any indication. Compounded injectable tesofensine preparations are produced outside the FDA drug approval pathway. Their use is the responsibility of the prescribing clinician and the informed patient in a supervised medical relationship.
Results: Individual results vary. Weight-loss percentages cited on this page refer to specific clinical trial populations under controlled conditions and may not represent outcomes in clinical practice or with compounded injectable formulations, which have not been studied in equivalent phase III trials.
Trademark: Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective holders. FormBlends has no affiliation with NeuroSearch, Novo Nordisk, Eli Lilly, or any pharmaceutical manufacturer referenced on this page. Brand names are used for informational comparison only.